Currently, Cramer sees two large macro-economic themes having major impact on the U.S. economy. First is oil, which has been covered endlessly since it began the rapid decline. The second is the nosedive in interest rates for the U.S. Treasury bonds, which could prove to be a big deal for the economy.
As a review, when the price of a Treasury goes up, the interest rate goes down, and vice versa. The foreign economic landscape has been treacherous as of late, thus money has been flooding into U.S. Treasuries as investors seek financial security.
The result of the incoming flooding of foreign money has sent Treasury prices higher and interest rates lower. How long can this rally really last, and how low can interest rates go?
Looking at the weekly chart of the iShares 20+ year Treasury ETF, otherwise known as the TLT, Garner sees that the U.S. Treasuries are dramatically overbought currently. That means the price of bonds came up way too quickly and could likewise be headed for a dramatic decline.
Read More Cramer's staggering prediction for Treasuries & USD
To continue with the "Mad Money" theme of finding the next generation of biotech this week, Cramer spoke with the CEO of Halozyme Therapeutics, Dr. Helen Torley.
Halozyme specializes in using human enzymes to alter the extracellular matrix, the area outside of the body that provides structural support for tissues.
Torley spoke to her excitement for Halozyme's pipeline when she stated, "A key reason that I joined Halozyme was because of the potential I saw for PH20. It attacks a sugar that accumulates around some cancers and prevents cancer from getting access."
In the Lightning Round, Cramer spotted the next MVP's when he gave his take on a few caller favorites:
Kinder Morgan: "We are not backing the truck up on anything on this roller coaster market. Should you pick KMI because it has a 5 percent yield, like my charitable trust did? Yes. But there are a lot of people who are dead set against all MLP's. This stock probably will go lower before it goes higher."
Isis Pharmaceuticals: "The one thing I do have to say is that it had a very bad aisle in reversal today. Which means it went up and came back down, which means the stock could use some work. If you want to jump in tomorrow, I think it can wait. Patience! This stock has been a rocket ship for heavens sake."
Read MoreLightning Round: Wait on this rocket ship stock